Credit: Arcutis. Zoryve cream contains roflumilast, a phosphodiesterase type 4 inhibitor. Zoryve (roflumilast) cream 0.15% is now available for the topical treatment of mild to moderate atopic ...

FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...

WESTLAKE VILLAGE, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company dedicated to developing meaningful innovations in ...

Incyte's cream for the treatment of moderate atopic dermatitis in adults has been recommended for approval by the European Medicines Agency. The agency issued a positive opinion on Incyte's Opzelura ...

New data from the Phase 3 INTEGUMENT-OLE long-term open label study show durable improvement in the signs and symptoms of atopic dermatitis (AD), including almost half of participants achieving no or ...

- The majority of patients, 51.9% (378/728), entered with or achieved complete disease clearance (vIGA-AD™=0) in the 48-week ADORING 3 open-label LTE study. - Most patients, 81.6% (594/728), entered ...

The efficacy of ruxolitinib cream in pediatric patients shows that nonsteroidal management of atopic dermatitis is feasible, said Lawrence Eichenfield, MD, chief of pediatric and adolescent ...

More patients treated with Vtama achieved vIGA-AD success compared with those who received vehicle cream in both ADORING 1 (45% vs 14%) and ADORING 2 (46% vs 18%). The Food and Drug Administration ...

Experts explain what causes eczema and how to deal with it. Credit...Lou Kiss Supported by By Katie Mogg When Oscar Brann imagined retirement, he pictured days spent fishing with his grandson, or ...

Discover safe hair removal tips for eczema-prone skin, including best methods, skin prep, product choices, and aftercare.